Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

Court of Appeals Affirms District Court Decision Invalidating Minerva Surgical Patent Asserted Against Hologic; The U.S. Court Of Appeals Rejected Minerva’s Arguments On Appeal And As A Result, Minerva Had To Pay Hologic More Than $7.4M

By Happy Mohamed
Today, 6:23 PM
Hologic, Inc. (NASDAQ:HOLX) announced today that the U.S. Court of Appeals for the Federal Circuit unanimously affirmed a 2021 district court ruling that invalidated a Minerva patent asserted against Hologic. The

HOLX

Read More
1 minute read

Pfizer And Valneva Announce That Pfizer, As The Study Sponsor, Has Decided To Discontinue A Significant Percentage Of Participants In The U.S. Who Had Been Enrolled In The Valor Phase 3 Study, Due To Violations Of Good Clinical Practice

By Benzinga Newsdesk
Today, 6:23 PM
The study is investigating the efficacy, safety, and immunogenicity of an investigational Lyme disease vaccine candidate, VLA15. These study participants, representing approximately half of the total recruited

PFE

Read More
3 minute read

Merck’s KEYTRUDA Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone In Patients With HER2-Negative Gastric Or Gastroesophageal Junction Adenocarcinoma Regardless Of PD-L1 Expression

By Happy Mohamed
Today, 6:23 PM
In KEYNOTE-859, KEYTRUDA combined with chemotherapy also showed statistically significant improvements in progression-free survival and objective response rate, the trial's key secondary endpoints, compared with

MRK